# A Clinical Trial Comparing the Tolerability of Etravirine to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Treatment-naive HIV-1 Infected Patients

> **NCT00903682** · PHASE2 · COMPLETED · sponsor: **Janssen-Cilag International NV** · enrollment: 157 (actual)

## Conditions studied

- HIV Infection
- HIV
- Acquired Immunodeficiency Syndrome

## Interventions

- **DRUG:** etravirine (ETR, TMC125)
- **DRUG:** efavirenz (EFV)

## Key facts

- **NCT ID:** NCT00903682
- **Lead sponsor:** Janssen-Cilag International NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2010-02
- **Final completion:** 2011-01
- **Target enrollment:** 157 (ACTUAL)
- **Last updated:** 2013-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00903682

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00903682, "A Clinical Trial Comparing the Tolerability of Etravirine to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Treatment-naive HIV-1 Infected Patients". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00903682. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*